Is the Simultaneously Integrated Boost (SIB) Technique for Early Breast Cancer Ready to Be Adopted for Routine Adjuvant Radiotherapy? Statement of the German and the Austrian Societies of Radiooncology (DEGRO/ÖGRO)

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2013 Jan 30

PMID 23358687

Citations 15

Authors

F Sedlmayer

M L Sautter-Bihl

W Budach

J Dunst

P Feyer

R Fietkau

W Haase

W Harms

C Rodel

R Souchon

F Wenz

R Sauer

Affiliations

Soon will be listed here.

Citing Articles

Low doses to the heart in daily practice for treating left-sided breast cancer using accelerated partial-breast irradiation by multicatheter brachytherapy and deep-inspiration breath-hold using a SIB.

Knippen S, Schonherr S, Schwedas M, Teichmann T, Howitz S, Maurer M Strahlenther Onkol. 2023; 199(4):389-395.

PMID: 36826517 PMC: 10033472. DOI: 10.1007/s00066-023-02047-z.

Long-term oncological outcomes of hypofractionated versus conventional fractionated whole breast irradiation with simultaneous integrated boost in early-stage breast cancer.

Lertbutsayanukul C, Pitak M, Nantavithya C Radiat Oncol J. 2022; 40(2):141-150.

PMID: 35796117 PMC: 9262705. DOI: 10.3857/roj.2021.00927.

Expert Discussion: Hypofractionated Radiation Therapy - Standard for All Indications?.

Fastner G, Krug D, Meattini I, Gruber G, Poortmans P Breast Care (Basel). 2022; 17(2):224-231.

PMID: 35707177 PMC: 9149542. DOI: 10.1159/000521552.

Prospective Study of Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer.

Bataille B, Raoudha B, Le Tinier F, Basson L, Escande A, Langin H Cancers (Basel). 2021; 12(12).

PMID: 33419316 PMC: 7766204. DOI: 10.3390/cancers12123852.

Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial.

Reimer T, Glass A, Botteri E, Loibl S, Gentilini O Cancers (Basel). 2020; 12(12).

PMID: 33317077 PMC: 7763449. DOI: 10.3390/cancers12123698.

References

Vrieling C, Collette L, Fourquet A, Hoogenraad W, Horiot J, Jager J . The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol. 2000; 55(3):219-32. DOI: 10.1016/s0167-8140(00)00210-3. View

Sautter-Bihl M, Budach W, Dunst J, Feyer P, Haase W, Harms W . DEGRO practical guidelines for radiotherapy of breast cancer I: breast-conserving therapy. Strahlenther Onkol. 2007; 183(12):661-6. DOI: 10.1007/s00066-007-1811-1. View

Bantema-Joppe E, van der Laan H, de Bock G, Wijsman R, Dolsma W, Busz D . Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: results on local control and survival. Radiother Oncol. 2011; 100(2):215-20. DOI: 10.1016/j.radonc.2011.05.027. View

Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J . Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005; 75(1):9-17. DOI: 10.1016/j.radonc.2005.01.005. View

Nestle-Kramling C, Bolke E, Budach W, Peiper M, Niederacher D, Janni W . [Hemangiosarcoma after breast-conserving therapy of breast cancer: report of four cases with molecular genetic diagnosis and literature review]. Strahlenther Onkol. 2011; 187(10):656-64. DOI: 10.1007/s00066-011-2251-5. View

Hurkmans C, Dijckmans I, Reijnen M, van der Leer J, van Vliet-Vroegindeweij C, Van der Sangen M . Adaptive radiation therapy for breast IMRT-simultaneously integrated boost: three-year clinical experience. Radiother Oncol. 2012; 103(2):183-7. DOI: 10.1016/j.radonc.2011.12.014. View

Whelan T, Pignol J, Levine M, Julian J, MacKenzie R, Parpia S . Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010; 362(6):513-20. DOI: 10.1056/NEJMoa0906260. View

Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D . Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol. 2012; 7:80. PMC: 3432009. DOI: 10.1186/1748-717X-7-80. View

Jagsi R, Ben-David M, Moran J, Marsh R, Griffith K, Hayman J . Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys. 2009; 76(1):71-8. PMC: 4414125. DOI: 10.1016/j.ijrobp.2009.01.041. View

10.

Yang Z, Chen J, Xie J, Zhu C, Pan Z, Yu X . Simultaneous integrated boost in breast conserving radiotherapy: is replanning necessary following tumor bed change?. Technol Cancer Res Treat. 2012; 12(2):115-22. DOI: 10.7785/tcrt.2012.500309. View

11.

Mukesh M, Harris E, Jena R, Evans P, Coles C . Relationship between irradiated breast volume and late normal tissue complications: a systematic review. Radiother Oncol. 2012; 104(1):1-10. DOI: 10.1016/j.radonc.2012.04.025. View

12.

Collette S, Collette L, Budiharto T, Horiot J, Poortmans P, Struikmans H . Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J Cancer. 2008; 44(17):2587-99. DOI: 10.1016/j.ejca.2008.07.032. View

13.

Baack T, Wenz F . Secondary cancers after radiotherapy may appear early and atypical. Strahlenther Onkol. 2011; 188(1):91-2. DOI: 10.1007/s00066-011-0019-6. View

14.

Hurkmans C, Meijer G, van Vliet-Vroegindeweij C, van der Sangen M, Cassee J . High-dose simultaneously integrated breast boost using intensity-modulated radiotherapy and inverse optimization. Int J Radiat Oncol Biol Phys. 2006; 66(3):923-30. DOI: 10.1016/j.ijrobp.2006.05.041. View

15.

Coles C, Yarnold J . The IMPORT trials are launched (September 2006). Clin Oncol (R Coll Radiol). 2006; 18(8):587-90. DOI: 10.1016/j.clon.2006.07.010. View

16.

Donovan E, James H, Bonora M, Yarnold J, Evans P . Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer. Med Phys. 2012; 39(10):5814-24. PMC: 3498624. DOI: 10.1118/1.4748332. View

17.

Chadha M, Vongtama D, Friedmann P, Parris C, Boolbol S, Woode R . Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer. 2011; 12(1):57-62. DOI: 10.1016/j.clbc.2011.09.002. View

18.

Moody A, Mayles W, Bliss J, AHern R, Owen J, Regan J . The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. Radiother Oncol. 1994; 33(2):106-12. DOI: 10.1016/0167-8140(94)90063-9. View

19.

Freedman G, Anderson P, Goldstein L, Ma C, Li J, Swaby R . Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys. 2007; 68(2):347-53. DOI: 10.1016/j.ijrobp.2006.12.035. View

20.

Bantema-Joppe E, Schilstra C, de Bock G, Dolsma W, Busz D, Langendijk J . Simultaneous integrated boost irradiation after breast-conserving surgery: physician-rated toxicity and cosmetic outcome at 30 months' follow-up. Int J Radiat Oncol Biol Phys. 2012; 83(4):e471-7. DOI: 10.1016/j.ijrobp.2012.01.050. View